AMENDMENTS TO THE CLAIMS

1. (currently amended): A method for treating an occult choroidal neovascular (CNV) lesion in a subject comprising

selecting a subject with an ~~with the~~ occult CNV lesion comprising an occult component of >50% and <100% of the lesion and assessed as (a) a small lesion with a size less than 5 disc areas, (b) poor visual acuity of less than 65 letters prior to treatment, or both (a) and (b); and

providing photodynamic therapy (PDT) to the subject having said ~~an occult~~ CNV lesion~~, wherein the subject is assessed as having either or both of (a) a small lesion with a size less than 5 disc areas or (b) poor visual acuity of less than 65 letters prior to treatment, wherein the occult lesion comprises an occult component of 50% to 100% of the lesion~~.

2. (original): The method of claim 1 wherein said subject was assessed by determining the size of said lesion and/or determining the best corrected visual acuity of the subject.

3-4. (canceled)

5. (previously presented): The method of claim 1 wherein the small lesion has a size less than 4 disc areas.

6. (currently amended): The method of claim 1, wherein said ~~the~~ occult CNV lesion is in a subject afflicted or diagnosed with age-related macular degeneration (AMD).

7. (original): The method of claim 1 wherein said PDT comprises the administration of a photosensitizer (PS).

8. (original): The method of claim 7, wherein the PS is administered at a concentration ranging between about 2 to 8 mg/m^2 (PS/body surface area of subject).

9. (original): The method of claim 8, wherein the PS is administered at a concentration of 6 mg/m^2.

10. (original): The method of claim 9, wherein the PS is a green porphyrin.

11. (original): The method of claim 10, wherein the green porphyrin is selected from BPD-DA, BPD-DB, BPD-MA, BPD-MB, EA6, and B3.

12. (original): The method of claim 11, wherein the green porphyrin is BPD-MA.

13. (original): The method of claim 10, wherein the PS is coupled to a specific binding ligand.

14. (original): The method of claim 7, wherein the PS is formulated with a carrier.

15. (original): The method of claim 14, wherein the formulation is selected from the group consisting of a liposome, emulsion, or aqueous solution.

16. (original): The method of claim 1, wherein said PDT comprises irradiation with electromagnetic radiation containing wavelengths in the visible light spectra.

17. (original): The method of claim 16, wherein the irradiation provides between 12.5 J/cm^2 and 100 J/cm^2.

18. (original): The method of claim 17, wherein said irradiation occurs between 5 to 30 minutes after administration of a photosensitizer.

19. (original): The method of claim 7, wherein the PS is administered at a concentration ranging between about 10 μg/kg to 100mg/kg (PS/body weight of subject).

20. (previously presented): The method of claim 1, wherein a resulting loss of visual acuity is less with treatment than without treatment.

21. (New): The method of claim 11, wherein the green porphyrin is EA6.